ViaGenetics® began as a technology company in 2013 and has now transitioned to research and drug development.

ViaGenetics built the world’s first genomic search engine and collaboration platform.


Now, ViaGenetics is using its genomic discoveries to reveal precursor factors to diagnose, prevent, treat or cure disease.

Our genomic platform is user-friendly by design, and fosters collaboration across all users, to include clinicians with little to no genomic or bioinformatics training.

Initial Beta Test Results:

50+ disease related genes discovered
80+ published papers

Meet the ViaGenetics® Team

Executive Management

Richard Postrel

CEO & Chief Innovation Officer

  • Sets the strategic policy and directs the intellectual property development
  • Selected by the National Academy of Science as one of the leading innovators in America in 2009
  • Specialist in intellectual property and an expert in process and methods with well over 100 patents

Steve Kerr

Chief Learning Officer & BoD Member

  • Chief Learning Officer and Managing Director at Goldman Sachs
  • Previously VP of Corporate Leadership Development and Chief Learning Officer at General Electric, responsible for GE's renowned leadership education center at Crotonville
  • Served on the faculties of Ohio State University, the University of Southern California, and the University of Michigan, and was Dean of the faculty of the USC business school from 1985 to 1989

Jeff Cummings, MD, ScD

Chief Science Officer

  • Leads the establishment of protocols and validation of the research
  • Multiple Alzheimer’s awards: i) Henderson Award of the American Geriatrics Society, ii) the Research Award of the John Douglas French Alzheimer’s Research Foundation and iii) the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association

Scientific Partners

Marni Falk, MD

Program Lead, Targeted Cancer

  • Executive Director of the CHOP Mitochondrial Medicine Center
  • PI of active NIH-funded research laboratory investigating the genetic etiologies, mechanisms, and therapies for mitochondrial diseases with over 85 publications

Cynthia M. Otto, DVM, Ph.D.

Project Leader

  • Professor within the University of Pennsylvania School of Veterinary Medicine
  • Current Research Interests are focused on the health, genetic and behavioral aspects of performance in detection dogs

Charlie Johnson, Ph.D.

Chief Nanotechnologist

  • Professor of Physics at the University of Pennsylvania
  • Director of Nano / Bio Interface Center
  • Research includes transport phenomena in nanoscale systems and hybrid nanostructures conjugated with proteins, synthetic peptides, and DNA

© 2017 ViaGenetics® All Rights Reserved.

(305) 865-7000

5244 North Bay Road, Miami Beach, FL 33140

© 2017 ViaGenetics® All Rights Reserved.